Sign in
Active, not recruitingEarly phase 1

Diclofenac as a KMO Inhibitor

Key facts

Who runs it
University of Maryland, Baltimore
Where
Catonsville, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Early phase 1
People taking part
12 people, planned
Started
31 Jul 2024
Ended
Aug 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Diclofenac
  • Placebo
Record updated
27 March 2026

Who can take part

Age
21 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Ages 21-65
  • Meet DSM-5 diagnostic criteria for AUD of any severity (Mild, Moderate, or Severe)

Who cannot take part

  • Currently on prescription medication that contraindicates use of diclofenac, including but not necessarily limited to: oral corticosteroids, anticoagulants, lithium, warfarin, aspirin (daily use), methotrexate, cyclosporine, ACE-inhibitors, and diuretics like furosemide and thiazides
  • Previously known hypersensitivity, including gastroenteritis, asthma, and allergic-type reactions, to any NSAID and/or aspirin
  • Current or recent (within 3 months) participation in a clinical trial involving medication administration
  • Currently in treatment, a history of treatment within the 30 days before enrollment, or currently seeking immediate treatment for AUD
  • Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders and bipolar and related disorders
  • Any autoimmune disorder, inflammatory disorder, or medical condition that may interfere with safe study participation and/or study aims (e.g., any cardiac, renal, or liver disease, uncontrolled hypertension, or diabetes)
  • Any lifetime history of ulcer disease, gastritis, gastroenteritis, or gastrointestinal bleeding
  • Currently prescribed a psychotropic medication for the treatment of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders
  • Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms
  • AST and ALT > four times the upper limit of the normal range, or albumin, GFR, BUN, or creatinine 15% > the upper limit of the normal range
  • Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12
  • Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants
  • Self-reported daily use of opioids (including prescribed)
  • Serious alcohol withdrawal symptoms as indicated by a score ≥ 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised
  • If female: pregnant, nursing, or with reproductive potential who refuses to use reliable methods of birth control throughout the study
  • Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year
  • Current daily use of any NSAID or regular pattern of near daily use within the past three months, regular use of a prebiotic or probiotic supplement and/or any antibiotic, prebiotic, or probiotic use within the last month
  • Current (last 12 months) DSM-5 diagnosis of SUD for any psychoactive substances other than alcohol and nicotine
  • Has below a 6th grade reading level
  • Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity

Where in United States

  • Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP)Catonsville, United States

About the trial

What the trial wants to find out

This mechanistic, proof of concept laboratory study will test the pharmacological properties of diclofenac in individuals with AUD. Participants will complete two sessions in which they will receive a single dose of diclofenac (100 mg) or matched placebo in a randomized and double blind fashion. The primary aim is to assess whether this dose of diclofenac, vs. placebo, increases circulating levels of kynurenic acid. This finding would provide evidence that diclofenac (100 mg) inhibits the kynurenine 3-monooxygenase enzyme.

The 2 groups in the trial

  • DiclofenacExisting treatment, for comparison

    Participants will take a single 100mg dose of diclofenac.

  • PlaceboPlacebo, for comparison

    Participants will take a single dose of placebo.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Proof of Concept: Diclofenac as a KMO Inhibitor in Individuals With Alcohol Use Disorder
Record updated
27 March 2026